Biocon Receives Another FDA Setback On Insulin Aspart

Further Complete Response Letter Issued After Inspection Not Scheduled Ahead Of Goal Date

 
• By David Wallace
  
Sign outside of FDA's headquarters in White Oak, MD
The FDA did not schedule a reinspection ahead of Biocon’s goal date • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products